Research programme: cadherin antagonists - Adherex Technologies
Latest Information Update: 23 Feb 2011
At a glance
- Originator McGill University
- Developer Adherex Technologies
- Class Organic chemicals; Peptides; Small molecules
- Mechanism of Action Cadherin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Aug 2006 The programme is available for collaboration (http://www.adherex.com/)
- 01 Apr 2005 This programme is still in active development
- 20 May 2003 Preclinical trials in Cancer in Canada (unspecified route)